1. Home
  2. UBXG vs SCLX Comparison

UBXG vs SCLX Comparison

Compare UBXG & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UBXG
  • SCLX
  • Stock Information
  • Founded
  • UBXG 2018
  • SCLX 2011
  • Country
  • UBXG China
  • SCLX United States
  • Employees
  • UBXG N/A
  • SCLX N/A
  • Industry
  • UBXG
  • SCLX Biotechnology: Pharmaceutical Preparations
  • Sector
  • UBXG
  • SCLX Health Care
  • Exchange
  • UBXG Nasdaq
  • SCLX Nasdaq
  • Market Cap
  • UBXG 38.2M
  • SCLX 35.7M
  • IPO Year
  • UBXG 2024
  • SCLX N/A
  • Fundamental
  • Price
  • UBXG N/A
  • SCLX $17.58
  • Analyst Decision
  • UBXG
  • SCLX Strong Buy
  • Analyst Count
  • UBXG 0
  • SCLX 3
  • Target Price
  • UBXG N/A
  • SCLX $367.50
  • AVG Volume (30 Days)
  • UBXG 734.4K
  • SCLX 309.9K
  • Earning Date
  • UBXG 01-01-0001
  • SCLX 08-13-2025
  • Dividend Yield
  • UBXG N/A
  • SCLX N/A
  • EPS Growth
  • UBXG N/A
  • SCLX N/A
  • EPS
  • UBXG N/A
  • SCLX N/A
  • Revenue
  • UBXG $39,603,353.00
  • SCLX $44,236,000.00
  • Revenue This Year
  • UBXG N/A
  • SCLX $89.26
  • Revenue Next Year
  • UBXG N/A
  • SCLX $203.95
  • P/E Ratio
  • UBXG N/A
  • SCLX N/A
  • Revenue Growth
  • UBXG N/A
  • SCLX N/A
  • 52 Week Low
  • UBXG $1.62
  • SCLX $3.60
  • 52 Week High
  • UBXG $9.92
  • SCLX $39.90
  • Technical
  • Relative Strength Index (RSI)
  • UBXG 35.32
  • SCLX 42.76
  • Support Level
  • UBXG $1.76
  • SCLX $14.80
  • Resistance Level
  • UBXG $1.94
  • SCLX $19.41
  • Average True Range (ATR)
  • UBXG 0.19
  • SCLX 3.44
  • MACD
  • UBXG 0.02
  • SCLX -1.41
  • Stochastic Oscillator
  • UBXG 27.42
  • SCLX 15.54

About UBXG U-BX Technology Ltd. Ordinary Shares

U-BX Technology Ltd is focused on providing value-added services using artificial intelligence-driven technology to businesses within the insurance industry, including insurance carriers and brokers. It helps institutional clients obtain visibility on various social media platforms and generate revenue based on consumers' clicks, views, or its clients' promotion time through those channels. The company derives a majority of its revenue by providing digital promotion services to its clients and also engages in providing risk assessment services, and value-added bundled benefits. It has developed an algorithm named Magic Mirror, to calculate payout risks for insurance carriers to underwrite auto insurance coverage. Geographically, all of the company's revenue is derived from Mainland China.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: